Background/Aims: Dysregulation of long noncoding RNAs (lncRNAs) is associated with the proliferation and metastasis in a variety of cancers, of which lncRNA maternally expressed gene 3 (MEG3) has been indicated as a tumor suppressor in multiple malignancies. However, the underlying mechanisms by which MEG3 contributes to human hemangiomas (HAs) remain undetermined. Methods: qRT-PCR analysis was performed to examine the expression levels of MEG3 and VEGF in proliferating or involuting phase HAs. MTT, colony formation assay, flow cytometry analysis and a subcutaneous xenograft tumor model were conducted to assess the effects of MEG3 on the HAs tumorigenesis. The interaction between MEG3 and miRNAs or their downstream pathways was evidenced by bioinformatic analysis, luciferase report assays, RNA immunoprecipitation (RIP) assay. and Western blot analysis. Results: The expression of MEG3 was substantially decreased and had a negative correlation with VEGF expression in proliferating phase HAs, as compared with the involuting phase HAs and normal skin tissues. Ectopic expression of MEG3 suppressed cell proliferation, colony formation and induced cycle arrest in vitro and in vivo, followed by the downregulation of VEGF and cyclinD1, but knockdown of MEG3 reversed these effects. Furthermore, MEG3 was verified to act as a sponge of miR-494 in HAs cells, and miR-494 counteracted MEG3-caused anti-proliferative effects by regulating PTEN/PI3K/AKT pathway, and exhibited the negative correlation with MEG3 and PTEN expression in proliferating phase HAs. Conclusion: Our findings suggested that lncRNA MEG3 inhibited HAs tumorigenesis by sponging miR-494 and regulating PTEN/ PI3K/AKT pathway.
Introduction
Hemangiomas (HAs) as one of the most common infantile tumors are benign vascular neoplasms, mainly shaped by the proliferating vascular endothelial cells [1] . According to the life span, HAs are divided into proliferating phase (rapid growth) and involuting phase HAs (spontaneous regression) [2] . The somatic mutations, such as von Hippel-Lindau (VHL) contribute to the development of HAs [3] . Our previous studies showed that insulin like growth factor 2 (IGF2)/IGF2R and vascular endothelial growth factor receptor 2 (VEGFR2) pathways promote HAs cell proliferation and reduce cell apoptosis [4, 5] but pharmacological inhibition of hypoxia inducible factor-1 (HIF-1) results in the growth inhibition in HAs cells [6] . However, little knowledge is known about the molecular mechanisms underlying HAs growth.
Long non-coding RNAs (lncRNAs), a group of non-coding transcripts that exceed 200 nucleotides in length, is associated with the proliferation, apoptosis and metastasis in a variety of cancers [7] [8] [9] , of which lncRNA maternally expressed gene 3 (MEG3) has been reported to be downregulated in multiple malignancies such as nasopharyngeal carcinoma [10] , tongue squamous cell carcinoma (TSCC) [11] , hepatocellular carcinoma (HCC) [12] , pituitary tumor [13] , thyroid carcinoma [14] , osteosarcoma [15] , and epithelial ovarian carcinoma [16] . Loss of MEG3 or its polymorphisms is associated with clinal stage, distant metastasis, unfavorable survival in patients with thyroid and ovarian carcinomas [14, 15] , and contributes to cell hypoxia injury [17] . MEG3 suppresses cell proliferation, cycle progression, invasion [10] [11] [12] [13] [14] and induces cell apoptosis [11] , leading to the tumorigenesis [16] . These studies suggest that MEG3 may act as a tumor suppressor and a potential biomarker in cancer.
LncRNA expression profiles have been used to identify the involvement of MEG3 in the pathogenesis of Infantile HAs [18] . In addition to the lncRNAs, microRNAs (miRNAs), a subgroup of ncRNAs with about 20 nucleotides that inhibit their target gene are differentially expressed in different phase HAs [19] . Some studies showed that miR-143, miR-199a and miR-130a are involved in regulating cell proliferation and invasion in HAs cells [20] [21] [22] . Nevertheless, little is known about the functions and underlying mechanisms of MEG3 in the pathogenesis HAs. In this study, we assessed the anti-proliferative role of MEG3 and its underlying mechanisms in HAs cells, and provided a potential therapeutic target for HAs patients.
Materials and Methods

Materials
Human HAs-derived endothelial cells (HDEC) and CRL-2586 EOMA cells used in our study were from Institute of Biochemistry and Cell Biology (Shanghai, PR, China), and stored at Laboratory of General Surgery, Xinhua Hospital. Selection of hyperplasia. The lentivirus mediated MEG3 overexpression vector, negative control vector and virion-packaging elements were from Genechem (Shanghai, PR, China), and MEG3 siRNA (si-MEG3), miR-494 mimic and inhibitor, PTEN overexpression plasmid and PTEN siRNA were from GenePharma (Shanghai, PR, China). The primers of MEG3, miR-494 and PTEN were synthesized by Sangon Biotech (Shanghai, PR, China), and the antibodies against VEGF, cylinD1, PI3K, p-PI3K AKT and p-AKT were from Abcam (Cambridge, MA, USA).
Clinical specimens
According to the Mulliken classification, the patients with HAs were divided into three groups: normal skin tissues (n=15), involuting phase HAs (n=15) and proliferating phase HAs (n=15), which were stored at the laboratory of the Department of General Surgery. Tissues and clinical information were obtained as part of an approved study at Shanghai Jiao Tong University School of Medicine. The HAs tissues were mainly from the infantile and children, of which 19 males and 11 females were included and their age ranged from 2 months to 11 years old (average 21 months). HAs tissues were diagnosed by two independent pathologists. All the HAs patients showed their written informed consent for their samples for the scientific research.
Cell isolation, culture and transfection
The specimens of human derived HAs were cultured by the method of tissue adherence combined with enzymatic digestion, and the second generation cells were sorted by flow cytometry and CD31 positive cells were sub-cultured. Cell morphological observation were performed as previously reported [4] [5] [6] 23] . The characteristics of HDEC were listed as follows: the nucleus of HDEC was very clear, the cells showed long spindle and polygonal, and the "vessel cavity" structure could be formed. The positive expression of PCNA and VEGF was confirmed to be increased in proliferating phase HAs but decreased in involuting phase HAs as previously reported [5, 6, 23] . HDEC and CRL-2586 EOMA cell lines were cultured in Dulbecco's Modified Eagle's medium (DMEM, Sigma, Aldrich, USA) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS, Sigma, Aldrich, USA), 100U/ml of penicillin and 100μg/ml of streptomycin (Invitrogen, Carlsbad, CA, USA), and were placed in a humidified atmosphere containing 5% CO2 at 37°C. MEG3 overexpression vector, miR-494 mimic or inhibitor and PTEN overexpression plasmid or PTEN siRNA were transfected into HAs cells, and the functional experiments were further conducted.
Quantitative real-time PCR (qRT-PCR)
To detect the expression levels of MEG3 and miR-494 in HDEC and CRL-2586 EOMA cells, qRT-PCR was conducted. Total RNA of each clone was extracted with TRIzol according to the manufacturer's protocol. Reverse-transcription was performed by using M-MLV and cDNA amplification by SYBR Green Master Mix kit. In addition, total RNA for miR-494 was isolated by using a High Pure miRNA isolation kit (Roche) and first-strand cDNA was synthesized using a TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Amplifications were performed using a miScript SYBR Green PCR kit and PCR moved on Applied Biosystems 7500 Real-Time PCR System (Applied Biosystems). The PCR primer sequences were listed as follows: miR-494 forward: 5'-ATGAGGCTTCAGTACTTT ACAG-3' and reverse:5'-CATAGCGTAAAAGGAGC AACA -3'; MEG3 forward: 5'-CTGCCCATCTACACCTCACG-3' and reverse: 5'-CTCTCCGCCGTCTGCGCTAG GGGCT-3'; PTEN forward: 5'-TTTGAAGACCATAACCCACCAC, reverse: ATTAC ACCAGTTCGTCCCTTTC; GAPDH forward: 5'-CAACGAATTTGGCTACAGCA-3' and reverse: 5'-AGGGGTCTACATGGCAACTG-3'. Three separate experiments were performed. PCR conditions were as follows: 94°C for 30 s, 56°C for 30 s, and 72°C for 90 s, with 30 cycles, and a final extension at 72°C for 5 min. Thus, the analysis of the relative gene expression data was conducted by using qRT-PCR and the 2 -ΔΔCT method. miR-494 expression was normalized to the U6 expression level and GAPDH expression was used as an internal control for PTEN. The experiments were performed three times.
Western blot assay HDEC and CRL-2586 EOMA cell lines were harvested and extracted using lysis buffer, and then equal amount of cell extracts were separated on 15% SDS-PAGE gels. Separated protein bands were transferred into polyvinylidene fluoride (PVDF) membranes and the membranes were blocked in 5% skim milk powder. The primary antibodies against VEGF, CyclinD1, PTEN, PI3K, p-PI3K, AKT, p-AKT were diluted according to the instructions of antibodies and incubated overnight at 4°C. Then, horseradish peroxidase-linked secondary antibodies were added at a dilution ratio of 1:1000, and incubated at room temperature for 2 h. The membranes were washed with PBS and the bands were visualized using ECL-PLUS/Kit according to the kit's instruction.
Cell viability assay
Cell viability was assessed by the MTT assay. Briefly, HA cells transfected with MEG3 and (or) miR-494 mimic were incubated in 96-well-plates with DEME medium supplemented with 10% FBS. Cells were treated with 10 μl MTT dye each day and then incubated with 150μl of DMSO for 15 min. The color reaction was measured at 570 nm with enzyme immunoassay analyzer (Bio-Rad, American).
Colony formation assay HDEC and CRL-2586 EOMA cells were trypsinized, and 1×10 3 cells were plated in 6-well plates and incubated at 37°C for 7 days. Colonies were dyed with dyeing solution containing 0.1% crystal violet and 20% methanol. Cell colonies were then counted and analyzed. Cell cycle analysis HDEC and CRL-2586 EOMA cells were incubated in serum-free medium for 24 h followed by transfection with MEG3 or si-MEG3 for 48h. Then cells were trypsinized, washed with PBS, fixed with 75% cold ethanol overnight at 4°C and washed with PBS again. Afterwards, the fixed cells were stained with PI in the presence of RNase A for 30 min in darkness. The samples were then analyzed on FACsort flow cytometer (Becton Dickinson, Mountain View, CA, USA). The percent cell count in different stages of cell cycle could be read according to PI fluorescence. ModFit3.0 software (Verity Software House, Topsham, ME, USA) was used for cell cycle analysis. The experiment was performed in triplicate.
Luciferase reporter assay
The fragments of MEG3 and 3′ UTR of PTEN, which included the predicted wild-type (WT) binding sites of miR-494 and mutant binding sites (Mut) were amplified by PCR and inserted into a pMIR-Report luciferase reporter vector (Ambion, Austin, TX, USA), termed as WT-MEG3, Mut-MEG3, WT PTEN 3′ UTR, and Mut PTEN 3′ UTR. HAs cells were seeded into 24-well plates. After 24h incubation, they were co-transfected with 200 ng constructed luciferase reporter vectors, and 50 μM miR-494 mimic, inhibitor or miR-NC. A luciferase reporter assay system (Promega Corporation, Fitchburg, WI, USA) was applied to analyze the luciferase activities at 48 h post transfection.
RNA immunoprecipitation (RIP)
RIP assay was carried out by using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore) according to the manufacturer's instructions. Antibodies for RIP assays against Ago2 and IgG were purchased from Abcam (ab5072, Rabbit polyclonal antibody, Cambridge, MA, USA).
Animal experiments
Six-week-old female immune-deficient nude mice (BALB/c-nu) were bred at the laboratory animal facility. All experimental procedures were performed according to the regulations and internal biosafety and bioethics guidelines of Xinhua Hospital, Shanghai Jiao Tong University. Mice were injected subcutaneously with 5x10 6 HDEC cells transfected with Vector or MEG3 (n=6). Mice were monitored daily and developed a subcutaneous tumor. The tumor volume every three days was measured with a caliper using the formula: volume = length x width 2 /2. RT-PCR analysis was performed to detect the expression levels of MEG3 and miR-494 in xenograft tumor samples.
Statistical analysis
Statistical analyses were conducted by using SPSS 20.0 (IBM, SPSS, Chicago, IL, USA) and GraphPad Prism. Student's t-test and Chi-square test were used to assess the statistical significance for the comparisons of two groups. The Pearson's correlation coefficient analysis was used to analyze the correlations between miR-494 expression and MEG3 or PTEN in HAs tissues. P < 0.05 was considered statistically significant.
Results
The expression levels of MEG3 and VEGF in different phase HAs
Our previous studies showed that VEGF expression can be used to differentiate the proliferating and involuting phase HAs by immunohistochemistry analysis [5] . Therefore, the expression levels of MEG3 and VEGF were estimated in different phase HAs (n=15) by qRT-PCR analysis, which indicated that MEG3 expression was downregulated (Fig. 1A) , but VEGF expression was upregulated in proliferating phase HAs as compared with the normal tissues and involuting phase HAs (Fig. 1B) . The Pearson analysis showed that MEG3 displayed a negative correlation with VEGF expression in proliferating phase HAs (r=-0.5368, P < 0.05) (Fig. 1C) , but had no correlation in involuting phase HAs (r=-0.1410, P > 0.05) (Fig. 1D) .
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LncRNA MEG3 repressed proliferation and colony formation in HAs cells
To uncover the functional role of MEG3 in HAs cells, MTT, colony formation assay and flow cytometry analysis were performed. After the lentivirus mediated MEG3 was transfected into HDEC and CRL-2586 EOMA cells for 48 h, its transfection efficiency was evaluated by qRT-PCR analysis (Fig. 2A) . The results showed that, overexpression of MEG3 suppressed the cell proliferation viability (Fig. 2B ) and colony formation ability (Fig. 2C, D) , and induced cell number increase in cycle G0/G1 phase but decrease in S phase (Fig. 2E, F) as compared with the control group. In addition, the expression levels of VEGF and cyclinD1 were examined by western blot analysis, and displayed a markedly decreased expression in HDEC and CRL-2586 EOMA cells after the transfection with MEG3 overexpression vectors (Fig. 2G, H) . 
LncRNA MEG3 acted as a sponge of miR-494 in HAs cells
To uncover the molecular mechanisms of MEG3 in HAs cells, the online bioinformatic microRNA.org software (http://www.microrna.org/microrna/home.do) was used to identify 14 miRNAs that have the potential to bind with MEG3 (Supplementary Table S1 -for all supplemental material see www.karger.com/10.1159/000496040/). According to the mirSVR and PhastCons scores, miR-494 harbored the greatest potential to bind with MEG3. Subsequently, the expression level of miR-494 was validated to be elevated in proliferating phase HAs as compared with the normal tissues and involuting phase ones, indicated by qRT-PCR analysis (Fig. 4A) , and had a negative correlation with MEG3 expression in proliferating phase HAs (r=-0.5315, P < 0.05) (Fig. 4B) , but possessed no correlation with MEG3 in involuting phase HAs (Supplementary Fig. S1A ). Fig. S1B ). After WT or Mut MEG3 report vector in combination with miR-494 mimic or inhibitor was co-transfected into HDEC and CRL-2586 EOMA cells for 48 h, the luciferase activity of WT MEG3 was dramatically reduced by miR-494 (Fig. 4D) , but increased by miR-494 inhibitor in HAs cells (Fig. 4E ), but the luciferase activity of Mut MEG3 was not impacted by miR-494 mimic or inhibitor in HAs cells (Fig. 4D, E) . Moreover, the expression level of miR-494 was also significantly decreased by MEG3 overexpression, but increased by MEG3 knockdown (Fig. 4F ), but that of MEG3 was not affected by miR-494 mimic or inhibitor in HAs cells (Supplementary Fig. S1C ). Furthermore, RIP assay was conducted for Ago2 protein in HAs cells and the expression levels of endogenous MEG3 and miR-494 pulled-down from AGO2-expressed cells were enriched in the Ago2 pellet compared with the input control, indicated by qRT-PCR analysis (Fig. 4G) .
MiR-494 counteracted MEG3-caused anti-proliferative effects by regulating PTEN/PI3K/ AKT pathway
MEG3 was confirmed to exhibit significant anti-proliferation effect in HAs cells on the fifth day (Fig. 2B) . After MEG3 or si-MEG3 vector in combination with miR-494 mimic or inhibitor was co-transfected into HDEC and CRL-2586 EOMA cells for 5 d, the decreased proliferation viability caused by MEG3 overexpression was reversed by miR-494 mimic (Fig. 5A) , while the increased proliferation viability by si-MEG3 was attenuated by miR-494 (Fig. 5B) . Moreover, it has been reported that miR-494 mimic promotes cell proliferation and migration and induces cell apoptosis by targeting PTEN in glioblastoma and HCC [23, 24] . According to the mirSVR and PhastCons scores, the online microRNA.org analysis identified the high binding affinity of miR-494 with 3'UTR of PTEN ( Supplementary  Fig. S1D ). Subsequently, qRT-PCR analysis showed that PTEN expression was dramatically decreased in proliferating phase HAs as compared with the normal tissues and involuting phase ones, and had a negative correlation with miR-494 expression in proliferating phase HAs (r=-0.5110, P < 0.05) (Fig. 5C ).
To reveal whether miR-494 can bind with the 3'UTR of PTEN, after WT or Mut 3'UTR of PTEN in combination with miR-494 mimic or inhibitor was co-transfected into HDEC and CRL-2586 EOMA cells for 48 h, the luciferase activity of WT PTEN 3'UTR was obviously reduced by miR-494 mimic (Fig. 5D) , and increased by miR-494 inhibitor in HAs cells (Fig.  5E ), but the luciferase activity of Mut PTEN 3'UTR was not altered by miR-494 mimic or inhibitor in HAs cells (Fig. 5D, E) . qRT-PCR analysis showed that miR-494 mimic reduced the expression level of PTEN, but miR-494 inhibitor increased its expression level in HAs cells (Supplementary Fig. S2 ). At last but not the least, the activity of PTEN and its downstream PI3K/AKT pathway was assessed by western blot analysis, indicating that MEG3 upregulated PTEN expression but caused the inactivation of the PI3K/AKT pathway, but these effects were reversed by miR-494 mimic in HDEC and CRL-2586 EOMA cells (Fig. 5F ).
PTEN mediated MEG3/miR-494 axis to regulate cell proliferation by PI3K/AKT pathway.
Having demonstrated the reciprocal interaction between miR-494 and PTEN ( Fig. 5C-E ) and the regulation of MEG3/miR-494 axis on PTEN/PI3K/AKT pathway (Fig. 5F ), we further investigated whether PTEN mediated MEG3/miR-494 axis to regulate cell proliferation by PI3K/AKT pathway. After miR-494 mimic and PTEN overexpression plasmid or miR-494 inhibitor and PTEN siRNA were co-transfected into HDEC or CRL-2586 EOMA cells for 5 d, miR-494-induced proliferation promoting effects were reversed by PTEN overexpression in HDEC, but miR-494 inhibitor-induced anti-proliferation effects were attenuated by PTEN knockdown in CRL-2586 EOMA cells (Fig. 6A) . Interestingly, we discovered that MEG3 induced anti-proliferation effects were reversed by PTEN knockdown in HDEC, whereas MEG3 knockdown-caused proliferation promoting effects were counteracted by PTEN overexpression in CRL-2586 EOMA cells (Fig. 6B) . Moreover, PTEN-mediated regulation of MEG3/miR-494 axis on the downstream PI3K/AKT pathway was evaluated by western blot analysis, indicating that PTEN overexpression decreased miR-494-induced activation of the PI3K/AKT pathway, but PTEN knockdown reversed MEG3 induced inactivation of the PI3K/ AKT pathway in HDEC (Fig. 6C) .
MEG3 inhibited HAs xenograft growth
The tumor suppressive role of MEG3 has been confirmed in HAs cells in vitro, and these effects were further validated in HAs xenograft tumors in vivo. A xenograft model was established to investigate the proliferative activity of HAs after subcutaneous inoculation with lentivirus-mediated MEG3 stably transfected HDEC cells. During the tumor proliferation phase, the average length and weight of the xenograft HAs were measured. As a consequence, the proliferative activity of the xenograft tumors was markedly lowered in MEG3 group as compared with the control group (Fig. 7A) . After HAs tissues were harvested, the average volumes and weight in MEG3 group were much smaller than the control group (Fig. 7B) . qRT-PCR analysis showed that MEG3 had the increased expression, but miR-494 harbored (Fig. 7C) , and the Pearson correlation analysis showed the negative association between MEG3 and miR-494 expression in these tumor samples in MEG3 group (r=-0.81, P < 0.05) (Fig.7D) .
Discussion
Accumulating data show that MEG3 is overexpressed in normal tissues [24] but downregulated in malignant tumors [10] [11] [12] [13] [14] [15] [16] . Low expression of MEG3 acts as an independent factor for predicting poor prognosis in cancer patients [12, 15, 25, 26] , and the downregulation of MEG3 is attributed to its promoter hypermethylation in cancer [27] [28] [29] , and the negative modulation by DNMT1 in glioma [30] . MEG3 and VEGF have the differential expression levels in HAs [5, 18] . In the present study, we found that, MEG3 expression was decreased and harbored the negative association with VEGF expression in proliferating phase HAs rather than in the involuting phase HAs, suggesting that MEG3 might be a negative regulator of HAs proliferation.
In regard to the functions of MEG3 in cancer, increasing evidence displayed that MEG3 decreases cell proliferation, invasion and metastasis [10-14, 24, 27] , and reverses the chemoresistance [24, 31] . Herein, our results illustrated that MEG3 repressed cell proliferation, colony formation and HAs xenograft tumorigenesis, but knockdown of MEG3 reversed these effects. As previously reported, VEGF and cyclinD1 as the proliferation and cycle related markers mediate key signaling pathways to regulate HAs cells [4] [5] [6] 32] . We found that, MEG3 downregulated VEGF and cyclinD1 expression in HAs cells, suggesting that MEG3 might inhibit HAs cell proliferation via inhibition of VEGF and cyclin D1 expression.
Mechanically, it is known that lncRNAs function as competing endogenous RNAs (ceRNAs) to regulate tumor progression by sponging miRNAs [33] [34] [35] . Some studies showed that MEG3 inhibits the tumorigenesis by sponging multiple miRNAs, such as miR-26a in TSCC [11] , miR-181a in gastric cancer [36] and miR-21 in cervical cancer [37] . We found that miR-494 was identified to have the potential to bind with MEG3 and exhibit the negative correlation with MEG3 expression in proliferating phase HAs or xenograft tumor tissues. MEG3 was further confirmed to act as a sponge of miR-494 in HAs cells.
According to the previous studies, miR-494 acts a dual role in tumors. On the one hand, miR-494 functions as a tumor suppressor in cancers [38, 39] . On the other hand, it exhibits an oncogenic role [40] by negatively regulating PTEN/PI3K/AKT pathway [41] . PTEN as a tumor suppressor is an antagonist regulator of the PI3K/AKT pathway, involved in the regulation of cerebral cavernous malformations [42] . Intriguingly, we discovered that miR-494 had the negative correlation with PTEN expression in HAs samples and exerted potential to bind with 3'UTR of PTEN. Moreover, MEG3 activated PTEN expression but inactivated the PI3K/ AKT pathway, while miR-494 counteracted MEG3-caused these effects on PTEN/PI3K/AKT pathway. Moreover, PTEN reversed miR-494 or MEG3 knockdown induced tumor promoting effects by inactivation of the PI3K/AKT pathway. These results suggested that MEG3 might sponge miR-494 to activate PTEN but inactivate PI3K/AKT pathway, and downregulate VEGF and cycinD1 expression, thereby causing the growth inhibition of HAs (Fig. 7E ).
Conclusion
Our findings demonstrated that lncRNA MEG3 inhibits the HAs tumorigenesis by sponging miR-494 and regulating PTEN/PI3K/AKT pathway, and provided a potential therapeutic target for HAs.
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